Home
News
Create
Screeners
Insights
Astal Laboratories
82.
99
-0.06
(-0.07%)
Market Cap
₹350.35 Cr
PE Ratio
35.34
Industry
Commercial Services
Buy
Sell
Company Performance:
1D
-0.07%
1M
-5.18%
6M
-14.14%
1Y
+2.95%
5Y
+848.46%
View Company Insights
Latest news about Astal Laboratories
Astal Laboratories Receives ₹29.57 Crore Investment Through Preferential Share Allotment
4 days ago
Astal Laboratories Limited completed a substantial preferential allotment of 29,56,666 equity shares on January 14, 2026, to non-promoter investors Suryanarayana Raju Rudraraju and Krishnaveni Rudraraju through a share swap arrangement. The transaction increased the company's equity share capital from ₹10.77 crores to ₹42.22 crores, representing an investment of approximately ₹29.57 crores. Suryanarayana Raju Rudraraju acquired 7.00% shareholding with 29,55,833 shares, while the remaining shares went to Krishnaveni Rudraraju. The company has complied with all SEBI regulatory requirements for substantial acquisition disclosures.
Astal Laboratories Receives Substantial Acquisition Disclosure for 48.67 Lakh Shares Through Preferential Allotment
4 days ago
Astal Laboratories: Kommera Harish Increases Stake to 6.67% Through Preferential Allotment
4 days ago
Astal Laboratories Completes ₹17.50 Crore Preferential Share Allotment to Non-Promoter Investors
4 days ago
Astal Laboratories Completes ₹277 Crore Sriven Pharmachem Acquisition Through Share Swap
Jan 01, 2026
More news about Astal Laboratories
29
Dec 25
Astal Lab Signs LOI with Immuna Therapeutics for CAR-T Cell Therapy Rights
Astal Laboratories has partnered with Switzerland-based Immuna Therapeutics GmbH through a Letter of Intent for exclusive India rights to next-generation CAR-T cell therapies. The collaboration includes technology transfer and localization in India, with the company now projecting ₹3,000 crore in incremental revenue, representing a significant increase from previous estimates.
25
Nov 25
Astal Laboratories Secures REACH Certification and Swiss Distribution Deal
Astal Laboratories Limited has obtained REACH compliance certification, enabling exports of specialty chemicals to the EU. The company also secured a Letter of Intent from a Swiss distributor for 60 tonnes of Piroctone Olamine, to be delivered between December 2025 and June 2026. These developments are expected to strengthen Astal's position in the European market and expand its international footprint.
09
Nov 25
Astal Laboratories Expands Authorized Share Capital to Rs 50 Crore
Astal Laboratories Limited has increased its authorized share capital from Rs 20 crore to Rs 50 crore, as approved by shareholders at an EGM on November 6, 2025. The number of equity shares has risen from 2,00,00,000 to 5,00,00,000, maintaining a face value of Rs 10 per share. The company has informed the BSE about this development on November 9, 2025, in compliance with SEBI regulations.
07
Nov 25
Astal Laboratories Holds EGM: Approves Share Capital Increase and Sriven Pharmachem Acquisition
Astal Laboratories Limited conducted an Extraordinary General Meeting on November 6, 2025, via video conferencing. The meeting focused on three key agenda items: increasing authorized share capital, acquiring a 100% stake in Sriven Pharmachem India Private Limited through equity share swap, and approving a related party transaction for the acquisition. The meeting was chaired by Dr. Radhakishore Pandrangi and attended by key directors. E-voting was conducted for all resolutions, with results to be announced within 48 hours.
03
Oct 25
Astal Laboratories to Consider Share Capital Increase and Acquisition in Upcoming Board Meeting
Astal Laboratories Limited has scheduled a board meeting for October 9, 2025, to discuss significant matters. Key agenda items include potential increase in authorized share capital, consideration of preferential issue of equity shares or convertible warrants, final decision on acquiring Sriven Pharmachem India Private Limited, and preparations for an Extraordinary General Meeting. The company has implemented a trading window closure from October 1, 2025, until 48 hours after the declaration of Q2 FY2026 results. Corporate governance measures include appointing a scrutinizer for the e-voting process.
Astal Laboratories
82.
99
-
0.
06
(-
0.
07
%)
1 Year Returns:
+2.95%
Industry Peers
Redington
250.70
(-
3.
35
%)
Elitecon International
72.13
(+
0.
17
%)
MMTC
63.83
(-
1.
69
%)
MSTC
455.70
(-
1.
53
%)
BN Agrochem
320.00
(-
1.
43
%)
Ravindra Energy
142.86
(-
1.
85
%)
Vintage Coffee & Beverages
147.59
(-
2.
82
%)
TCC Concept
400.00
(-
2.
38
%)
Creative Newtech
694.80
(+
0.
14
%)
Polo Queen Industrial And Fintech
26.88
(-
1.
50
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation